News Releases

Anixa Biosciences and MolGenie Announce Early Potency Analysis of SARS-CoV-2 Protease Inhibitor

January 24, 2022

Anixa Biosciences to Participate in Upcoming January Investor Conferences: LifeSci Partners Annual Corporate Access Event and H.C. Wainwright BioConnect Conference

December 16, 2021

Anixa Biosciences and MolGenie Announce that their COVID-19 Compounds are Expected to be Effective Against the Omicron Variant

December 7, 2021

Anixa Biosciences Announces Patient Dosing of its Investigational Vaccine Candidate in a First-of-its-Kind Preventative Breast Cancer Vaccine Study

October 26, 2021

Anixa Biosciences Announces First Chinese Patent on its CAR-T Cancer Therapy Technology

October 6, 2021

Anixa Biosciences Announces Notice of Allowance for Additional Patent on its CAR-T Cancer Therapy

October 1, 2021

Anixa Biosciences' Ovarian Cancer CAR-T Therapy to be Discussed at Upcoming Emerging Immunotherapeutics for Ovarian Cancer Symposium

September 14, 2021

Anixa Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

September 8, 2021

Anixa Biosciences Appoints Dr. Pamela Garzone As Chief Development Officer

September 7, 2021

Anixa Biosciences and Moffitt Cancer Center Announce FDA Clearance to Initiate Clinical Trial of Ovarian Cancer CAR-T Immunotherapy

August 30, 2021

« Previous
1...
2
3
4
5
6
7
8
9
10
11
...25
Next »

Latest News & Events

Sep 18, 2024

Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Therapy at the Ovarian Cancer Research Alliance's International Gynecologic Cancer Conference

Read More...

Sep 3, 2024

Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Therapy at the Rivkin Center-AACR 15th Biennial Ovarian Cancer Research Symposium

Read More...

Aug 26, 2024

Anixa Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Read More...